Tackling CV Risk in Type 2 Diabetes -- Gaps Between Guidelines and Clinical Practice?

Introduction/Overview

Controlling Glycemia Reduces Microvascular Complications: DCCT

Prevalence Rates of CV Comorbidities in Persons With T2DM: Results of a Systematic Literature Review

LEADER: Primary Outcome Liraglutide vs Placebo

SUSTAIN-6 (Semaglutide): Primary Outcome Results

Albiglutide: Results From the HARMONY Outcomes Trial

GLP-1 RAs and Improved Cardiac Function

EMPA-REG Primary Outcome (3-Point MACE): CV Death, Nonfatal MI, or Nonfatal Stroke

EMPA-REG: Results for CV Death and HHF

CANVAS (SGLT2i): Cardiovascular Results

DECLARE TIMI-58 (Dapagliflozin): MACE Results

Pharmacologic Therapy for T2DM: ADA/EASD 2018 Recommendations

New Paradigm for Treating the Patient With Both T2DM and CVD

The Kidneys and SGLT2 Inhibitors

Potential Mechanisms for CV Benefit Associated With Empagliflozin

Glucose Reduction and GLP-1RAs: Results Form the LEAD Trials

Despite Proven Advantages, Use of Newer Glucose-Lowering Agents Remains Low

Cardiologists Prescribing Anti-Hyperglycemics?

Summary and Conclusions

Abbreviations

Abbreviations (cont)